The severity of infection induces a shift in the type 1/type 2 T-helper cell balance in patients with or without peritonitis

Surgical Infections

Volumn 4, Issue 3, 2003, Pages 247-254

  Russ, Martin A ^a   Reith, H Bernd ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DIVERTICULITIS; FLOW CYTOMETRY; GREATER OMENTUM; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MORTALITY; MULTIPLE ORGAN FAILURE; PERITONITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

EID: 0242407426     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/109629603322419580     Document Type: Article

References (17)

1. Farthmann EH, Schöffel U. Principles and limitations of operative management of intra-abdominal infections. World J Surg 1990;14:210-217.
2. Hammond JM, Potgieter PD. The influence of surgery on cytokines in patients with intra-abdominal sepsis. Anaesth Intensive Care 1996;24:430-434.
3. Hamilton G, Hofbauer S, Hamilton B. Endotoxin, TNF-alpha, interleukin-6 and parameters of the cellular immune system in patients with intraabdominal sepsis. Scand J Infect Dis 1992;24:361-368.
4. Riche FC, Cholley BP, Panis YH, et al. Inflammatory cytokine response in patients with septic shock secondary to generalized peritonitis. Crit Care Med 2000; 28:433-437.
5. Debets JM, Kampmeijer R, van der Linden MP, et al. Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 1989;17:489-494.
6. Bone RC, Fisher CJ Jr, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317:653-658.
7. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis syndrome: A randomized, controlled, double-blind, multicenter clinical trial. JAMA 1995;273:934-941.
8. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: A randomized, double-blind, placebo-controlled trial. N Engl J Med 1991;324:429-436.
9. O'Sullivan ST, Lederer JA, Horgan AT, et al. Major injury leads predominance of the TH 2 lymphocyte phenotype and diminished IL-12 production associated with decreased resistance to infection. Ann Surg 1995; 222:482-487.
10. Zedler S, Bone RC, Baue AE, et al. T-cell reactivity and its predictive role in immunosuppression after burns. Crit Care Med 1999;31:66-72.
11. Curley PJ. Endotoxin, cellular immune dysfunction and acute pancreatitis. Shock 2000;13:79-82.
12. Rostaing L, Puyoo O, Tkaczuk J, et al. Differences in type 1 and type 2 intracytoplasmic cytokines, detected by flow cytometry, according to immunosuppression (cyclosporine A vs. tacrolimus) in stable renal allograft recipients. Clin Transpl 1999;13:400-409.
13. van den Berg AP, Twilhaar WN, van Son WJ, et al. Quantification of immunosuppression by flow cytometric measurement of intracellular cytokine synthesis. Transpl Int 1998;11:S318-S321.
14. Bone RC, Grodzin CJ, Balk RA. Sepsis: A new hypothesis for pathogenesis of the disease process. Chest 1997;121:235-243.
15. Hensler T, Hecker H, Heeg K, et al. Distinct mechanisms of immunosuppression as a consequence of major surgery. Infect Immun 1997;65:2283-2291.
16. Ferguson NR, Galley HF, Webster NR. T helper cell subset ratios in patients with severe sepsis. Intensive Care Med 1999;25:106-109.
17. Heidecke CD, Hensler T, Weighardt H, et al. Selective defects of T lymphocyte function in patients with lethal intraabdominal infection. Am J Surg 1999;178: 288-292.